<DOC>
	<DOCNO>NCT00391846</DOCNO>
	<brief_summary>The purpose study HF treatment guide NTproBNP addition clinical symptom sign effective treatment guide clinical symptom sign alone patient HF leave ventricular systolic dysfunction</brief_summary>
	<brief_title>Evaluation Heart Failure Treatment Guided N-terminal Pro B-type Natriuretic Peptide ( NTproBNP ) v Clinical Symptoms Signs Alone</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Ventricular Dysfunction</mesh_term>
	<mesh_term>Ventricular Dysfunction , Left</mesh_term>
	<mesh_term>Signs Symptoms</mesh_term>
	<mesh_term>Ramipril</mesh_term>
	<mesh_term>Enalapril</mesh_term>
	<mesh_term>Lisinopril</mesh_term>
	<mesh_term>Captopril</mesh_term>
	<mesh_term>Trandolapril</mesh_term>
	<mesh_term>Carvedilol</mesh_term>
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Metoprolol</mesh_term>
	<mesh_term>Bisoprolol</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<mesh_term>Eplerenone</mesh_term>
	<mesh_term>Diuretics</mesh_term>
	<mesh_term>Natriuretic Peptide , Brain</mesh_term>
	<criteria>Female/male , 18 year previously verify HF leave ventricular systolic dysfunction . New York Heart Association ( NYHA ) class IIIV , NTproBNP males &gt; 800 ng/L , females &gt; 1000 ng/L Planned CV hospitalisation , stroke acute myocardial infarction ( MI ) last 3 month , Mitral/aortic stenosis , Patients already receive optimal HF treatment , Severe reduction kidney function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Heart Failure</keyword>
	<keyword>Ventricular Dysfunction</keyword>
	<keyword>NTproBNP</keyword>
</DOC>